Running a successful clinical trial is as much about execution as science. How can you tell which studies are best positioned to end on time with high-quality data?
We'll discuss the practical factors that add risk to clinical trials and how top biopharma companies get studies over the finish line with speaker Ken Getz, executive director and professor at the Tufts Center for the Study of Drug Development (Tufts CSDD) and the founder and board chair of the Center For Info & Study on Clinical Research Participation (CISCRP).
REGISTER
More on clinical trials:
- A delay in a clinical trial can signal more bad news to come. But not all delays are red flags. How often is a pushed-back timeline a bad omen? And how can you predict the difference? This STAT Report explains.
- Explore STAT Trials Pulse by AppliedXL, an advanced early warning system for clinical trial updates.
No comments